BMO Capital initiated coverage of Medpace (MEDP) with a Market Perform rating and $600 price target The firm views the stock’s valuation as full in a “tepid” biotech funding backdrop. The shares at current levels leave “little cushion for additional potential macro volatility,” the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace Holdings Inc: Key Update on the OPAL Study for Lymphoid Malignancies
- Medpace and AVM Biotechnology’s Promising ARDS Study: A Potential Game Changer
- Medpace and Telix Collaborate on Promising Phase 3 Study for Advanced Kidney Cancer
- Medpace and Radiopharm Launch Promising Cancer Study with 177LuBetaBart
- Medpace and Radiopharm Theranostics Advance Brain Metastases Imaging Study